Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract

Aliment Pharmacol Ther. 2005 Sep 1;22(5):417-22. doi: 10.1111/j.1365-2036.2005.02567.x.

Abstract

Background: Biliary secretion of antibiotic agents into the bile is considerably compromised by biliary obstruction, a precondition of bacterial cholangitis. Moxifloxacin may be advantageous according to secretion and antimicrobial spectrum.

Aim: To establish the secretion of moxifloxacin into obstructed and non-obstructed bile.

Methods: Biliary excretion of moxifloxacin was determined in plasma and bile of 10 patients with biliary obstruction and cholangitis and 10 patients without biliary obstruction 30 min after administration of 400 mg of moxifloxacin intravenously.

Results: The plasma concentration of moxifloxacin was similar in both groups (4.45 +/- 1.58 microg/mL; 4.33 +/- 1.23 microg/mL). The concentration of moxifloxacin in the bile was significantly lower in patients with biliary obstruction than without (4.63 +/- 3.94 microg/mL; range 0.71-14.40; vs. 16.90 +/- 13.77 microg/mL; range 1.79-42.50; P = 0.043). Although significantly different, the penetration index was extensively high in those without biliary obstruction (4.41 +/- 4.40; range 0.35-14.45) but still sufficient in those patients with obstructive cholangitis (1.02 +/- 0.74; range 0.29-2.83; P = 0.035).

Conclusion: These findings are suggestive of an active secretion mechanism for moxifloxacin into the obstructed bile, producing a biliary concentration sufficiently above the minimal inhibitory concentrations for most of the expected bacteria.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aza Compounds / adverse effects
  • Aza Compounds / blood
  • Aza Compounds / pharmacokinetics*
  • Bile / chemistry
  • Biliary Tract / metabolism*
  • Cholangiopancreatography, Endoscopic Retrograde
  • Cholangitis / metabolism*
  • Cholestasis / metabolism*
  • Female
  • Fluoroquinolones
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Moxifloxacin
  • Quinolines / adverse effects
  • Quinolines / blood
  • Quinolines / pharmacokinetics*

Substances

  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Moxifloxacin